Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Blog Pricing

Dr. Rachel Bedard

๐Ÿ‘ค Speaker
379 total appearances

Appearances Over Time

Podcast Appearances

Search Engine
What we got wrong about GLP-1s

Insulin helps your muscles take the glucose out of your blood into the muscle and use it for energy.

Search Engine
What we got wrong about GLP-1s

What happens in people of type 2 diabetes or people of prediabetes is they develop insulin resistance, which means that they have decreased response to insulin, which means they are less effective at taking the glucose out of your blood.

Search Engine
What we got wrong about GLP-1s

And that means that your body needs to release more insulin in order to take that glucose out of your blood.

Search Engine
What we got wrong about GLP-1s

Yeah.

Search Engine
What we got wrong about GLP-1s

So for diabetics...

Search Engine
What we got wrong about GLP-1s

who often have very high levels of glucose just like circulating in the blood.

Search Engine
What we got wrong about GLP-1s

High levels of glucose is called hyperglycemia.

Search Engine
What we got wrong about GLP-1s

It has all sorts of downstream effects.

Search Engine
What we got wrong about GLP-1s

It hurts your eyes, it hurts your kidneys.

Search Engine
What we got wrong about GLP-1s

Eventually, it contributes to plaque buildup in your arteries, which can cause heart attacks and strokes.

Search Engine
What we got wrong about GLP-1s

So what you want to do in diabetics is get their glucose levels, their average circulating glucose levels down.

Search Engine
What we got wrong about GLP-1s

And GLP-1 agonists help do that by signaling to your pancreas when you have a glucose spike to release insulin so that the glucose spike doesn't spike too high.

Search Engine
What we got wrong about GLP-1s

Basically, it helps sort of maintain your glucose levels within a range that your body can handle.

Search Engine
What we got wrong about GLP-1s

And GLP-1 agonists, through that sort of combination of effects, the semaglutide, like, wugoviozempics, lead to, like, 10 to 15% body weight loss over the course of a year in the studies.

Search Engine
What we got wrong about GLP-1s

But the thing that I think is really interesting about these drugs, and one of the reasons that they've inspired so much excitement, is because they've had effects that we sort of anticipated that were, like, targeted effects in the initial trials.

Search Engine
What we got wrong about GLP-1s

improved blood sugar control and weight loss.

Search Engine
What we got wrong about GLP-1s

And then they've had a bunch of unexpected downstream effects probably related to weight loss and better blood sugar control, like they prevent heart attacks, they prevent strokes, they prevent people from progressing to diabetic kidney disease.

Search Engine
What we got wrong about GLP-1s

They seem to improve people's knee arthritis, which, like, was really unexpected.

Search Engine
What we got wrong about GLP-1s

They seem to improve heart failure.

Search Engine
What we got wrong about GLP-1s

And then they also have this potential effect around addiction.